Q2 FY26 · Ended Jun 30, 2026 · View SEC filing
Overhead growth swallowed most of the sales gain
Revenue rose 23.5% but operating income only 7.1%, because selling and administrative costs grew by a third in a year.
For investorsWhat has to go right for Insulet's operating margin to recover?
For foundersSelling the device as a consumable: the playbook behind Omnipod
Last year's quarter carried an $84.4M debt repurchase loss, so the comparison flatters; operating income grew far less.
Free cash flow fell to $55.9M from $177.9M as working capital and plant spending absorbed cash.
A pump worn for up to three days and then replaced turns each patient on therapy into recurring revenue.
Unlock the financial breakdown, competitive insights, historical trends and founder playbook, plus research across the company library.
Free CXProWealth membership required
Business Lens describes Insulet Corporation from its own filings with the SEC. It is not a view on its shares, a target, or advice to buy, sell or hold anything; figures are as filed and may be restated by the company later. The filing is linked above.
